Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates
Completed single ascending dose (SAD) portion of Phase 1 trial evaluating OV329, a potential next-generation GABA-aminotransferase inhibitor Executed equity investment...